(Q36709001)

English

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

scientific article published on 28 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

multicenter clinical trial

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

4

object named as

Mark R Litzow

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Joshua F Zeidner

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Matthew C Foster

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Amanda L Blackford

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Lawrence E Morris

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Stephen A Strickland

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jeffrey E Lancet

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Prithviraj Bose

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Yair Levy

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Raoul Tibes

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Ivana Gojo

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Christopher D Gocke

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Gary L Rosner

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Richard F Little

14

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

John J Wright

15

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

L Austin Doyle

16

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

B Douglas Smith

17

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Judith E Karp

18

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

publication date

28 May 2015

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

100

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1172-1179

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Age and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

30 September 2017

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

5 September 2018

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

5 September 2018

NCCN Clinical Practice Guidelines Acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

5 September 2018

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

5 September 2018

Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

5 September 2018

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

5 September 2018

Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800702

5 September 2018

Value of routine 'day 14' marrow exam in newly diagnosed AML

1 reference

https://pubmed.ncbi.nlm.nih.gov/26022709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26022709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A two-step timed sequential treatment for acute myelocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26022709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26022709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26022709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26022709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2015.125849

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36709001&oldid=1647139686"